en · de · es · pt
lab-handbook.peptides5388.com › Faq › Background And Receptor Pharmacology — Complete Guide

Background And Receptor Pharmacology — Complete Guide

By Editorial Desk · published 2026-02-18 · last reviewed 2026-04-10 · Faq

A practical reference on certificate of analysis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-04-10 and is reviewed periodically as new material appears.

Background and Receptor Pharmacology

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.

Analytical Detection and Storage

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistBinds REV-ERBα and REV-ERBβ in preclinical models
Molecular formulaC20H24ClN3O4SReported for the parent compound
CAS Registry Number1379686-30-2Common identifier in chemical databases
AppearanceOff-white to pale yellow solidTypical research chemical solid
SolubilitySoluble in DMSO and ethanol; low in waterClass: small organic molecule

Background and Mechanism

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Related pages on this site

Analytical Detection and Stability

Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Background and Research Status

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Supporting material

=== Collagen === Lin and her lab use molecular dynamics simulations to understand how the structure, stability, and interactions of collagen are perturbed by Gly to Ser substitutions, a very common type of Gly missense mutations in patients with Osteogenesis Imperfecta (OI), and Ser phosphorylation. Their results suggest a new possible mechanism underlying OI pathology, specifically that mutations may significantly disrupt the triple-helical structure of collagen and render it susceptible to non-collagenase proteolytic enzymes.

Pharmacokinetics is often studied using mass spectrometry because of the complex nature of the matrix (often blood or urine) and the need for high sensitivity to observe low dose and long time point data. The most common instrumentation used in this application is LC-MS with a triple quadrupole mass spectrometer. Tandem mass spectrometry is usually employed for added specificity. Standard curves and internal standards are used for quantitation of usually a single pharmaceutical in the samples. The samples represent different time points as a pharmaceutical is administered and then metabolized or cleared from the body. Blank or t=0 samples taken before administration are important in determining background and ensuring data integrity with such complex sample matrices. Much attention is paid to the linearity of the standard curve; however it is not uncommon to use curve fitting with more complex functions such as quadratics since the response of most mass spectrometers is less than linear across large concentration ranges. There is currently considerable interest in the use of very high sensitivity mass spectrometry for microdosing studies, which are seen as a promising alternative to animal experimentation. Recent studies show that secondary electrospray ionization (SESI) is a powerful technique to monitor drug kinetics via breath analysis. Because breath is naturally produced, several datapoints can be readily collected. This allows for the number of collected data-points to be greatly increased. In animal studies, this approach SESI can reduce animal sacrifice.

In English, it can also be called sea mustard. In Chinese, it is called qúndài cài (裙带菜) or hǎidài yá (海帶芽). In French, it is called wakamé or fougère des mers ('sea fern'). In Korean, it is called miyeok (미역).

After Best died in 1978 and complete documentation (including Banting's papers and Macleod's account of events) became available through the Thomas Fisher Rare Book Library, historian Michael Bliss compiled a comprehensive account of the events surrounding the discovery of insulin. Notably, Bliss's account reviews the nominations and Nobel Prize committee's own investigations that culminated in the 1923 decision.

Sources: en.wikipedia.org

Supporting material

== Background == The value of urine for diagnostic purposes has been recognized since ancient times. Urine examination was practiced in Sumer and Babylonia as early as 4000 BC, and is described in ancient Greek and Sanskrit texts. Contemporary urine testing uses a range of methods to investigate the physical and biochemical properties of the urine. For instance, the results of the routine urinalysis can provide information about the functioning of the kidneys and urinary system; suggest the presence of a urinary tract infection (UTI); and screen for possible diabetes or liver disease, among other conditions. A urine culture can be performed to identify the bacterial species involved in a UTI. Simple point-of-care tests can detect pregnancy by identifying the presence of beta-hCG in the urine and indicate the use of recreational drugs by detecting excreted drugs or their metabolites. Analysis of abnormal cells in urine (urine cytology) can help to diagnose some cancers, and testing for organic acids or amino acids in urine can be used to screen for some genetic disorders.

Angus Monfries (born 19 January 1987) is a former professional Australian rules footballer who played for the Essendon Football Club and Port Adelaide Football Club in the Australian Football League (AFL). Monfries played as a forward pocket or half forward.

Despite early success, some of the main hinderances of the UPP project were police abuses and disappearances that occurred. One of the most prominent cases of this was the disappearance of Amarildo Souza, a bricklayer from the Rocinha favela. Souza, 42, had been fishing the morning of his disappearance and decided to go into the favela to get produce when he was confronted by UPP officers. Souza was taken for questioning and subsequently never returned home. Souza was well known throughout Rocinha, leading to public outcry at his disappearance and a lack of response by the UPP unit. After more than two months of public outcry, an investigation was opened into his disappearance, where twenty-four UPP officers and the UPP commander were found accused of torture, concealing a body, procedural fraud, and conspiracy. In the subsequent trial, twelve officers would be found guilty of torture, procedural fraud, and concealing a body. Despite the investigation and criminal case, the UPP suffered weakened support from favela residents, who felt both anger and fear at the actions of the local UPP unit. Coupled with insufficient training and poorly strategized growth of the units, the UPP continued to fail as insignificant funding heavily derailed the project, which could not perform what it was intended to. With the weakening of the UPP, criminal organizations could again attempt to reclaim their territories through shootouts and confrontations, but were this time more successful.

=== High Voltage Power Corporation === In July 1968, High Voltage Engineering Corporation and Reynolds Metals Company announced they would form a joint venture partnership to develop, produce, and sell gas-insulated systems for transmission of electric power. The venture, High Voltage Power Corporation, aimed to commercialize technology for underground electric power transmission. HVEC president Denis Robinson noted increasing need by bury transmission lines underground for technological, economic, and aesthetic reasons, and emphasizing that compressed gas offered unique advantages for transmitting large amounts of power at high voltages with increased reliability at lower cost. Each company held a 50% interest in the venture, with Reynolds providing funds and technical research while HVEC contributed its patents, licenses, and know-how. The development work was carried out at HVEC's Burlington factory. The subsidiary's products included insulating-core reactors for nuclear power plants and gas-insulated transmission systems for electrical utilities, based on Van de Graaff's insulating-core transformer invention. However, by 1974, High Voltage Power Corp. losses were consuming 60-75% of HVEC's cash flow despite generating only $1.5-2 million in annual sales, leading HVEC to divest from the subsidiary.

Inkjet (dot on demand or continuous) systems are capable of printing high resolution (300 dpi or higher for dot on demand) images at press speed (up to 1000fpm). These solutions can be deployed either on-press or off-line. Laser marking can be employed to ablate a coating or to cause a color change in certain materials. The advantage of laser is fine detail and high speed for character printing, and no consumables. Not all substrates accept a laser mark, and certain colors (e.g. red) are not suitable for barcode reading. Thermal Transfer and Direct Thermal. For lower speed off-press applications, thermal transfer and direct thermal printers are ideal for printing variable data on labels. Software systems are available for managing traceability throughout the entire production, processing, marketing and distribution system. Some of these software systems combine multiple software modules allowing the producer to capture traceability information from all farming, processing and packing activities. Others, capture data in the field and packing operations to integrate with retail buying platforms and carry data all the way to the end consumer. Leveraging new advancements in mobile technology, food brands are now incorporating mobile messaging and QR codes on product labels. Consumers can text or scan the barcode with smartphones for immediate retrieval of product information. Consumers can also trace the origins of their purchased produce at websites.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.

Is SR9009 a hormone?

No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.

What is known about human use?

Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.

How is SR9009 measured?

Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.

Network